Bristol-Myers Squibb's (BMY) recent activities display a quickly growing trend. With a return of 2.4% over the last five years, BMY has become an investors' favourite. In the recent J.P. Morgan's 43rd Annual Healthcare Conference, the company announced their operational progress and future steps. Furthermore, the pharmaceutical giant has had significant clinical triumphs with the approvals of Opdivo Qvantig, an injectable cancer drug, and Breyanzi, a new CAR T cell therapy for patients suffering from mantle cell lymphoma. Institutional investors have shown great interest in BMY, with the company enjoying 78% institutional ownership. BMY also raised its dividend to $0.62, attracting both investors and analysts attention. Legal troubles hasn't slowed down BMY's progress as they emerged victorious in a $6.4 billion lawsuit over a delayed cancer drug. Following Q3 successes, anticipation surrounds the Q4 results due for release in February 2025. BMY's CAR T cell therapy Breyanzi also received approval for usage in relapsed or refractory follicular lymphoma cases. The overall activities of the company indicate a strong upward trend, as noted by CAN SLIM investing system's 83 RS Rating.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Fri, 03 Jan 2025 22:45:21 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor 4
